338 related articles for article (PubMed ID: 36949264)
1. New insights toward molecular and nanotechnological approaches to antidiabetic agents for Alzheimer's disease.
Pradhan SP; Sahu PK; Behera A
Mol Cell Biochem; 2023 Dec; 478(12):2739-2762. PubMed ID: 36949264
[TBL] [Abstract][Full Text] [Related]
2. New views and possibilities of antidiabetic drugs in treating and/or preventing mild cognitive impairment and Alzheimer's Disease.
Zhong KL; Chen F; Hong H; Ke X; Lv YG; Tang SS; Zhu YB
Metab Brain Dis; 2018 Aug; 33(4):1009-1018. PubMed ID: 29626315
[TBL] [Abstract][Full Text] [Related]
3. Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones.
Cardoso S; Moreira PI
Int Rev Neurobiol; 2020; 155():37-64. PubMed ID: 32854858
[TBL] [Abstract][Full Text] [Related]
4. Antidiabetic Drugs in the Treatment of Alzheimer's Disease.
Michailidis M; Tata DA; Moraitou D; Kavvadas D; Karachrysafi S; Papamitsou T; Vareltzis P; Papaliagkas V
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563031
[TBL] [Abstract][Full Text] [Related]
5. Antidiabetic Polypill Improves Central Pathology and Cognitive Impairment in a Mixed Model of Alzheimer's Disease and Type 2 Diabetes.
Infante-Garcia C; Ramos-Rodriguez JJ; Hierro-Bujalance C; Ortegon E; Pickett E; Jackson R; Hernandez-Pacho F; Spires-Jones T; Garcia-Alloza M
Mol Neurobiol; 2018 Jul; 55(7):6130-6144. PubMed ID: 29224179
[TBL] [Abstract][Full Text] [Related]
6. Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease.
Alagiakrishnan K; Sankaralingam S; Ghosh M; Mereu L; Senior P
Discov Med; 2013 Dec; 16(90):277-86. PubMed ID: 24333407
[TBL] [Abstract][Full Text] [Related]
7. Repurposing and clinical attributes of antidiabetic drugs for the treatment of neurodegenerative disorders.
Birajdar SV; Mazahir F; Alam MI; Kumar A; Yadav AK
Eur J Pharmacol; 2023 Dec; 961():176117. PubMed ID: 37907134
[TBL] [Abstract][Full Text] [Related]
8. Antidiabetic Drugs in Alzheimer's Disease: Mechanisms of Action and Future Perspectives.
Femminella GD; Bencivenga L; Petraglia L; Visaggi L; Gioia L; Grieco FV; de Lucia C; Komici K; Corbi G; Edison P; Rengo G; Ferrara N
J Diabetes Res; 2017; 2017():7420796. PubMed ID: 28656154
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic and Etiological Similarities in Diabetes Mellitus and Alzheimer's Disease: Antidiabetic Drugs as Optimistic Therapeutics in Alzheimer's Disease.
Das S; Ramachandran AK; Halder D; Akbar S; Ahmed B; Joseph A
CNS Neurol Disord Drug Targets; 2023; 22(7):973-993. PubMed ID: 35770411
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis.
Cao B; Rosenblat JD; Brietzke E; Park C; Lee Y; Musial N; Pan Z; Mansur RB; McIntyre RS
Diabetes Obes Metab; 2018 Oct; 20(10):2467-2471. PubMed ID: 29790638
[TBL] [Abstract][Full Text] [Related]
11. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2.
Plastino M; Fava A; Pirritano D; Cotronei P; Sacco N; Sperlì T; Spanò A; Gallo D; Mungari P; Consoli D; Bosco D
J Neurol Sci; 2010 Jan; 288(1-2):112-6. PubMed ID: 19836029
[TBL] [Abstract][Full Text] [Related]
12. Glibenclamide mitigates cognitive impairment and hippocampal neuroinflammation in rats with type 2 diabetes and sporadic Alzheimer-like disease.
Esmaeili MH; Enayati M; Khabbaz Abkenar F; Ebrahimian F; Salari AA
Behav Brain Res; 2020 Feb; 379():112359. PubMed ID: 31733313
[TBL] [Abstract][Full Text] [Related]
13. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?
Akter K; Lanza EA; Martin SA; Myronyuk N; Rua M; Raffa RB
Br J Clin Pharmacol; 2011 Mar; 71(3):365-76. PubMed ID: 21284695
[TBL] [Abstract][Full Text] [Related]
14. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives.
Ferrari F; Moretti A; Villa RF
Pharmacol Ther; 2022 Nov; 239():108277. PubMed ID: 36064147
[TBL] [Abstract][Full Text] [Related]
15. Type 2 Diabetes Mellitus Drugs for Alzheimer's Disease: Current Evidence and Therapeutic Opportunities.
Meng L; Li XY; Shen L; Ji HF
Trends Mol Med; 2020 Jun; 26(6):597-614. PubMed ID: 32470386
[TBL] [Abstract][Full Text] [Related]
16. Diabetic Theory in Anti-Alzheimer's Drug Research and Development - Part 1: Therapeutic Potential of Antidiabetic Agents.
Jankowska A; Wesołowska A; Pawłowski M; Chłoń-Rzepa G
Curr Med Chem; 2020; 27(39):6658-6681. PubMed ID: 31604406
[TBL] [Abstract][Full Text] [Related]
17. Antidiabetic Drugs in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review.
Muñoz-Jiménez M; Zaarkti A; García-Arnés JA; García-Casares N
Dement Geriatr Cogn Disord; 2020; 49(5):423-434. PubMed ID: 33080602
[TBL] [Abstract][Full Text] [Related]
18. New treatment approaches for Alzheimer's disease: preclinical studies and clinical trials centered on antidiabetic drugs.
Katsenos AP; Davri AS; Simos YV; Nikas IP; Bekiari C; Paschou SA; Peschos D; Konitsiotis S; Vezyraki P; Tsamis KI
Expert Opin Investig Drugs; 2022 Jan; 31(1):105-123. PubMed ID: 34941464
[TBL] [Abstract][Full Text] [Related]
19. Diabetes drugs in the fight against Alzheimer's disease.
Boccardi V; Murasecco I; Mecocci P
Ageing Res Rev; 2019 Sep; 54():100936. PubMed ID: 31330313
[TBL] [Abstract][Full Text] [Related]
20. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease.
Yarchoan M; Arnold SE
Diabetes; 2014 Jul; 63(7):2253-61. PubMed ID: 24931035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
